Mdm2 and p53 Expression in Radiation-Induced Sarcomas of the Head and Neck: Comparison with De Novo Sarcomas

다국어 초록 (Multilingual Abstract)

Background: The pathogenesis of radiation-induced sarcomas (RISs) is not well known. In RIS, TP53 mutations are frequent, but little is known about Mdm2-p53 interaction, which is a recent therapeutic target of sarcomas. Methods: We studied the immunohistochemical expression of Mdm2 and p53 of 8 RISs. The intervals between radiation therapy and diagnosis of secondary sarcomas ranged from 3 to 17 years. Results: Mdm2 expression was more common in de novo sarcomas than RISs (75% vs 37.5%), and p53 expression was more common in RISs than in de novo cases (75% vs 37.5%). While half of the RISs were Mdm2(–)/p53(+), none of de novo cases showed such combination; while half of de novo sarcomas were Mdm2(+)/p53(–), which are a candidate group of Mdm2 inhibitors, only 1 RIS showed such a combination. Variable immunoprofiles observed in both groups did not correlate with tumor types, except that all of 2 myxofibrosarcomas were Mdm2(+)/p53(+). Conclusions: In conclusion, we speculated that both radiation-induced and de novo sarcomagenesis are not due to a unique genetic mechanism. Mdm2-expression without p53 overexpression in 1 case of RIS decreases the future possibility of applying Mdm2 inhibitors on a subset of these difficult tumors.

참고문헌 (Reference)

1 Bjerkehagen B, "Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival?" 106 : 297-306, 2012

2 Gonin-Laurent N, "Specific TP53 mutation pattern in radiation-induced sarcomas" 27 : 1266-1272, 2006

3 Rumenapp C, "Secondary radiation-induced bone tumours demonstrate a high degree of genomic instability predictive of a poor prognosis" 13 : 433-437, 2012

4 Thijssens KM, "Radiation-induced sarcoma: a challenge for the surgeon" 12 : 237-245, 2005

5 Bjerkehagen B, "Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital" 47 : 1475-1482, 2008

6 Wei Z, "Radiation-induced sarcoma of head and neck: 50 years of experience at a single institution in an endemic area of nasopharyngeal carcinoma in China" 29 : 670-676, 2012

7 Wei Z, "Radiation-induced sarcoma in the head and neck region: a clinicopathologic and immunohistochemical study of 13 cases" 12 : 2995-2999, 2011

8 Xi M, "Radiation-induced sarcoma in patients with nasopharyngeal carcinoma: a single-institution study" 116 : 5479-5486, 2010

9 Gonin-Laurent N, "RB1 and TP53 pathways in radiation-induced sarcomas" 26 : 6106-6112, 2007

10 McHugh JB, "Primary versus radiation-associated craniofacial osteosarcoma: biologic and clinicopathologic comparisons" 107 : 554-562, 2006

11 Murray EM, "Postradiation sarcomas: 20 cases and a literature review" 45 : 951-961, 1999

12 Chan JY, "Postradiation sarcoma after radiotherapy for nasopharyngeal carcinoma" 122 : 2695-2699, 2012

13 Hameed M, "Pathology and genetics of adipocytic tumors" 118 : 138-147, 2007

14 Coindre JM, "Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma" 16 : 256-262, 2003

15 Canner JA, "MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53" 101 : 774-781, 2009

16 Barone G, "MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance" 15 : 114-123, 2014

17 Binh MB, "MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data" 29 : 1340-1347, 2005

18 Sabah M, "Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade" 15 : 64-69, 2007

19 Wu H, "Immunohistochemical analysis for Mdm2 and p53 proteins in methylcholanthrene-induced mouse rhabdomyosarcomas" 68 : 427-431, 2006

20 Roch-Lefevre S, "Cytogenetic and molecular characterization of plutonium-induced rat osteosarcomas" 51 : 243-250, 2010

21 Ohnstad HO, "Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma" 119 : 1013-1022, 2013

22 Le Guellec S, "Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?" 38 : 293-304, 2014

23 Hadj-Hamou NS, "A transcriptome signature distinguished sporadic from postradiotherapy radiation-induced sarcomas" 32 : 929-934, 2011